Introduction
In recent years, several synthetic cannabinoid compounds, first developed by researchers to study the cannabinoid receptor (CBIR) system in man, have become popular recreational drugs of abuse because of their psychoactive properties. These compounds became available through Internet resources in the mid-2000s under the general brand name 'Spice'. Aroma, K2, Bonzai and Dream were examples of this evolving group of smokable products referred to as 'Spice' and found by users to have potent cannabis-like effects.
Most of the synthetic cannabinoids are structurally distinct from tetrahydrocannabinol (THC), however, HU-210, which has the classical cannabinoid structure, has been identified in seizures (1) . Early on, cyclohexanols (e.g. CP47,497-analogues) were identified as active ingredients in Spice products as were several different naphthoylindoles and phenylacetylindoles (2, 3) . Many variations in naphthoylindoles and phenylacetylindoles were designed, synthesized and named by J.W. Huffman (4, 5) . More recently, a second generation of synthetic cannabinoids grouped as benzoylindoles (e.g. AM-694 and RCS-4) have been identified in products bought from the Internet (6 -8) , and the active agents in these products seem to be in constant change, being a step ahead of legislation (6, 9) . The increasing reports on the use of synthetic cannabinoids prompted regulators in Sweden to formally schedule a range of substances from 2009 and onwards. Table I summarizes the scheduling dates for those presently regulated in Sweden.
After the discovery that the central nervous system receptor (CB1R) and the peripheral receptor (CB2R) mediates physiological effects such as analgesia, antinausea, appetite stimulating effects and immunomodulatory effects, many compounds have been investigated for their possible therapeutic use (10, 11) . It has proved difficult, however, to separate the desired properties from unwanted psychoactive effects. A number of binding experiment measuring the affinity and efficacy of cannabinoid receptor ligands have been performed for CB1R and CB2R (4, 12) . Several of the compounds show very high CB1R affinities, in particular, JWH-122 (K i ¼ 0.69 nM) and JWH-210 with K i ¼ 0.46 nM (4) . JWH-018 (K i ¼ 9 nM), JWH-203 (K i ¼ 8 nM) and JWH-250 (K i ¼ 11 nM) activate CB1Rs with a potency and an efficacy greater than or equal to those of D 9 -THC (K i ¼ 10.2 nM) (5, 13). Many of the synthetic cannabinoids act as full agonists and activate CB1Rs with a potency greater than that of THC. The frequently occurring compounds, JWH-018 and JWH-081, have been studied in vitro for their CB1R affinity and in vivo for their pharmacological actions in rodents (5) . JWH-081 shows a very high affinity for the CB1R with K i ¼ 1.2 nM and was very potent in rodent experiments (12) .
In addition to psychoactive effects that are elicited by CB1R activation in humans, acute administration of THC or other CB1R agonists in rodents results in quantifiable actions, typically measured as a 'tetrad' of effects composed of analgesia, catalepsy, hypothermia and decreased locomotor activity (11) . The pharmacology or structure -activity relationships for a few synthetic cannabinoids have been evaluated in a mouse model. The pharmacological profile for JWH-018 and JWH-081, compared with THC, showed greater in vivo potency (5, 12, 13) . However, the pharmacological and toxicological profiles for many of the synthetic cannabinoids are unknown and future investigations are needed.
While smoking of marijuana produces relatively mild acute side effects in most users, it very rarely causes the adverse effects observed rather commonly with similar use of synthetic cannabinoids, such as hypertension, agitation, hallucinations, psychosis, anxiety, seizures and panic attacks (1, 2, 14 -16) . The mechanism behind these adverse effects is not completely understood; however, seizures caused by JWH compounds are possibly due to antagonism of neuronal inhibitory networks, such as gamma-aminobutyric acid (GABA) channels, and activation of excitatory networks, such as metabotropic glutamate receptors, Na þ channels and Ca 2þ channels (17) . Theories underlying the neurobiological mechanism of hallucinations and psychosis include abnormal dopaminergic neurotransmission, as described in the dopamine hypothesis of schizophrenia, serotonergic transmission, as seen with the serotonergic hallucinogens, and NMDA glutamate receptor blockade (18 -20) . The cardiovascular symptoms, drug-induced anxiety, agitation and panic attacks, associated with use of synthetic cannabinoids, could be caused by activation of a 1 , b 1 and b 2 adrenoreceptors (21) (22) (23) (24) (25) . Several deaths associated with synthetic cannabinoids have been reported even though it is unclear to what extent the cannabinoids contributed to death (26, 27) .
In addition to acute adverse effects produced by synthetic cannabinoids, one case report indicates that chronic abuse may also result in severe withdrawal and dependence syndrome (28) . Reports of animal experiments measuring 'hazard', reward and dependency by self-administration experiments or conditioned place preference experiments for many of the synthetic cannabinoids are inadequate today.
Up to date, there are several methods published detailing the identification of synthetic cannabinoids in blood and urine using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS), and more than 20 cannabinoids have been detected in spice products (2, 8, (29) (30) (31) .
The pharmacokinetic profiles, on the other hand, are little investigated partly because of the lack of ethical considerations for dosing studies in humans with more or less unknown compounds. However, Teske et al. (32) reported a method for the identification and quantitation of JWH-018 in serum by LC-MS-MS and reported serum peak concentrations in two human volunteers of 10 ng/mL five minutes after smoking. Traces of JWH-018 were still present in serum up to 48 h after smoking. Kacinko et al. (33) validated an LC-MS-MS method for the identification and quantification of JWH-018, -JWH-073 and JWH-250 in whole blood and reported whole blood peak concentrations of 5 ng/mL for both JWH-018 and JWH-073 19 min after smoking, a herbal incense blend containing both compounds.
Less than 2 h after smoking, the blood concentrations were ,1 ng/mL. Dresen et al. (34) described an LC-MS-MS method to detect and quantify several cannabinoids in the JWH series in human serum. In samples from 80 forensic cases from Germany before or during 2010, the most prevalent compounds were JWH-081 found in 56 samples ranging from 0.11 to 16.9 ng/mL followed by JWH-250 (n ¼ 47, 0.14 -18.1 ng/mL). JWH-018 was found in nine samples ranging from 0.30 to 8.17 ng/mL, and JWH-073 in six samples in concentrations ranging from 0.23 to 0.6 ng/mL.
Shanks et al. (27) developed a method to quantify JWH-018 and JWH-073 in postmortem whole blood using ultra performance LC (UPLC)-MS-MS. In samples from autopsy cases, they reported JWH-018 from 0.1 to 199 ng/mL and results for JWH-073 between 0.1 and 68.3 ng/mL.
It seems that LC-MS-MS is an appropriate technique to measure synthetic cannabinoids that contain one or more nitrogen atoms, whereas the HU-and CP-47 homologues might be better analyzed using GC-MS. Depending on the ionization mode, LC-MS-MS might also be useful for the CP-47 homlogues (35) .
The background of this study was an increase in cases that presented with unremarkable or negative routine toxicology, but where the subjects were severely impaired or even unconscious when found by the police. Some admitted to having smoked Spice products. This prompted us to develop a method for the detection of synthetic cannabinoids in whole blood.
This paper presents toxicological findings of synthetic cannabinoids in whole blood from some cases of severe intoxication including quantitative data from a large population of recreational users and a fatal intoxication.
Experimental

Recreational users
In total, 3,078 blood samples from subjects suspected of petty drug offence or driving under the influence of drugs (DUIDs) were analyzed using the described method. Yearly, the Swedish police sends samples from 38,000 petty drug offences and 12,000 DUID cases. In 5% of the cases, the police requested the analysis of synthetic cannabinoids. In some cases, the police reported the signs of impairment and symptoms of the suspects.
Fatal intoxication
A 17-year-old young male was found dead outdoors. In his pocket, a parcel with a brochure labeled 'Smoke XXX. A potent potpourri' together with a foil of herbs was found (sent by post 4 days earlier). A friend of the deceased told the police that he and the deceased had smoked the mixture of herbs. The friend took only two whiffs and felt dizzy and lost his perception of touch in his hands and after that went indoors. The deceased continued smoking outdoors alone. The temperature during the night was 6 -88C. The only toxicological finding was JWH-210, 12 ng/g femoral blood. The deceased had a low body mass index (BMI) of 16.4. The total weight of the lungs was 1264 g consistent with lung edema. Taken together, the circumstances, the histological and toxicological findings pointed toward intoxication. The cause of death was determined as hypothermia in Preparation of calibrators, controls and internal standard Individual 10 mg/mL stock standard solutions of all the 29 compounds were made in methanol and used to prepare mixed stock standard solutions containing 0.1, 0.01 and 0.001 mg/mL in methanol. These stock standards were spiked into 1.0 g blank bovine whole blood to prepare calibrators at the following concentrations: 0.05, 0.1, 1.0 and 5.0 ng/g. Quality control (QC) standards containing all the 29 analytes were prepared in methanol at 0.2 and 0.005 mg/mL and used to prepare high and low concentration QCs at 0.1 and 4.0 ng/g, respectively, in whole blood. A stock JWH-018-D 11 internal standard (IS) was prepared at 10 mg/mL in methanol and further diluted with methanol to a working concentration of 0.025 mg/mL. All stock and working standards were stored at 2208C.
Sample preparation To 1.0 g blood, 40 mL of JWH-018-D 11 solution (0.025 mg/mL) was added as IS. After addition of 0.5 mL Tris buffer (0.5 M, pH 8.5) and 3 mL of tert-butylmethylether : chlorobutane (50 : 50), the sample was vortex mixed for 10 min and then centrifuged. The aqueous phase was frozen at 2808C for 15 min, and the organic phase was decanted to clean tubes and evaporated to dryness under nitrogen at 408C. Samples were reconstituted in 100 mL of 10 mM ammonium formate and acetonitrile (50 : 50), transferred to autosampler vials and 5 mL injected into the LC-MS-MS.
Instrumentation
The LC-MS-MS system consisted of a Waters ACQUITY UPLC w (ultra performance LC) with a Binary Solvent Manager, Sample Manager and Column Manager (Waters, Milford, MA, USA) connected to an API 4000 TM triple-quadrupole instrument (AB Sciex, Stockholm, Sweden) equipped with an electrospray interface (TURBO V TM source, TurboIonSpray w probe) operating in the scheduled multiple reaction monitoring mode. Two transitions were measured for each compound (Table II) . Ion spray voltage was set to 5,000 V. Nitrogen was used as the nebulizer gas (345 kPa), heater gas (517 kPa at 5008C), curtain gas (207 kPa) and collision-activated dissociation gas (set on 5). UPLC was performed using an ACQUITY UPLC high-strength silica (HSS) T3 column (1.8 mm, 50 Â 2.1 mm, Waters) preceded by a 0.2-mm column filter (Waters) and operated at 0.6 mL/min with a total run time of 7 min. Mobile Phase A consisted of 0.05% formic acid in 10 mM ammonium formate and Phase B was 0.05% formic acid in acetonitrile. The chromatographic system was run in a linear gradient from 35 to 75% Phase B in 6 min then increased and held at 95% Phase B for 0.5 min followed by a 0.5-min equilibration at 35% Phase B. The injection volume was 5 mL and the column temperature was maintained at 608C. Instrument control, integration and calculation were performed using the Analyst TM 1.5 software. Identification was based on qualifier ratios compared with mean ratios from the daily calibrators.
Method validation
Selectivity was investigated by analyzing blood samples from 10 drug-free donors. To decide the calibration model that best described the relationship between the concentration and response for each compound, six replicates of calibrators at six levels were extracted and analyzed. Linear and quadratic models with and without weighting were evaluated. Residual plots were used to visually inspect the results, and a 10% mean deviation from the target value was considered acceptable.
Matrix effects were studied quantitatively using the postextraction spiking method described by Matuszewski et al. (36) . Drug-free donor blood samples were prepared by spiking prior to extraction (set C) and after extraction (set B) and the analyte areas compared with those from standards dissolved in mobile phase (set A). Matrix effects were defined as B/A and extraction recovery as C/B. A recovery of .50% was acceptable, and the matrix effects were evaluated together with the precision and accuracy experiments.
The precision and bias of the method was studied within series (n ¼ 5) and between series (n ¼ 10) at two levels, two times the limit of quantitation (LOQ) and at 80% of the calibration range. At the low level, accuracy and imprecision of ,20% were acceptable. At the high level, an accuracy of 15% and an imprecision of ,20% were acceptable. Dilution integrity was investigated by adding 50 ng/g of selected analytes (AM-2201, JWH-018, JWH-122, JWH-203, JWH-210, MAM-2201 and UR-144) to whole blood and dilute aliquots 16 times before analysis in triplicates. A mean deviation of 15% from the target value was acceptable.
Results
The selectivity experiments showed no interfering peaks at the retention times of the analytes. An example of a chromatogram is shown in Figure 1 . The analytes are spread out over the chromatographic range, but some analytes did co-elute.
For all analytes, the calibration model that best fitted the data was a quadratic function with a 1/Â weighting. The intra-and interday precision and bias are presented in Table III together with the matrix effect experiments. Matrix effects were seen and cannot be expected to be compensated by the single IS. However, only AM-1241, JWH-147, JWH-015 and JWH-073-methyl deviated .15% from the target value in the accuracy experiments and only JWH-398 had a between-day imprecision higher than 20%. Apart from that, the precision and accuracy experiments were acceptable. The dilution experiments resulted in an underestimation between 5 and 13% for the analytes and showed that samples could be diluted up to 16 times with acceptable precision.
The mean (median) age of the suspects was 22 (20) years and 88% were male. A summary of the quantitative findings in the positive cases is presented in Table IV . Of the 3078 analyzed samples, 28% were positive for one or more synthetic cannabinoid(s). Fourteen of the 29 analytes were found and the most common finding was AM-2201 with 451 findings, 244 of which as single positives. Of the positive cases, 60% had 1, 27% had 2, 11% had 3 and 2% had 4 or more synthetic cannabinoids present in their blood. The most common combinations, from the end of 2011 to early 2013, were AM-2201 and JWH-122 (n ¼ 52) and MAM-2201 and UR-144 (n ¼ 52), followed by AM-2201 and JWH-018 (n ¼ 50). In Table V , toxicological findings and circumstances for eight cases are presented. The cannabinoid concentrations in several of these intoxication cases were above the 90 percentile described in Table IV and, for JWH-018 and JWH-203, they presented the highest concentrations measured in our 862 positive cases. Figure 2 shows the percentage of positive findings for the seven most common analytes over time emphasizing the appearance and disappearance of drugs.
Discussion
The developed method was used to confirm the presence of synthetic cannabinoids in 3,078 whole blood samples with a positivity rate of 28%. The analysis was performed only in cases where the police had requested analysis of synthetic cannabinoids, which might explain the high percentage positive samples. Some of the analytes that were included in the validation did not meet the criteria for a quantitative method, but may be reported as present. These were AM-1241, JWH-147, JWH-015 and JWH-073-methyl. Several of the analytes (including those just mentioned) did not present with any positive samples, and we believe that this was a result of the changing drug panorama where several of the early scheduled drugs never hit the market at all. We also experienced a shift in positive analytes when All concentrations are by weight measured in whole blood (1 mL whole blood equals 1.055 g).
Table III
Accuracy and precision (within-and between-day), matrix effects and recovery data for all compounds at 0.1 ng/g (low) and 4.0 ng/g (high) Name Accuracy (%) within-day (n ¼ 5) substances were scheduled. The analytical method was modified to include emerging substances, but there was probably a timedelay between a new substance appearing on the market and the inclusion in the method. This delay is inevitable because reference substances have to be available before the validation and inclusion can be effective. Therefore, the appearance of UR-144 and MAM-2201 may have occurred much earlier than shown in There are very few quantitative data for the different synthetic cannabinoids published. In a large number of forensic cases, Kneisel and Auwa¨rter (37) reported median concentrations of ,1 ng/mL serum for JWH-018, JWH-019, JWH-081, JWH-122, JWH-203, JWH-210 and AM-2201. These results are in serum and cannot be directly compared with our data in whole blood, as the blood : serum ratios for these substances are unknown. A reasonable extrapolation from THC would propose that the serum concentrations are higher than that in whole blood. In our data set, all analytes except RCS-4 had median concentrations of ,0.5 ng/g and confirm those reported by Kneisel and Auwa¨rter as well as others. We also add new data for some of the emerging drugs MAM-2201 and UR-144. Based on its lower affinity for the CB1R, UR-144 should present with higher concentrations. However, this does not seem to be the case in our population of recreational users. In summary, the concentrations are very low and sensitive methods are necessary to both screen and confirm the presence of synthetic cannabinoids in blood. A cutoff of 0.05 ng/g blood is probably required to detect the majority of positive cases.
Despite cannabis being a commonly abused drug, there are few reports of severe intoxications. In comparison with cannabis, the synthetic cannabinoids seem to be more dangerous and potent causing several unwanted symptoms in the users (15, (38) (39) (40) (41) (42) . It is expected that the increased potencies exhibited by many of the cannabinoid agonists will lead to increased adverse effects. We present eight cases of severe intoxication where synthetic cannabinoids were the only drugs found in the blood of the subjects. Blood samples were taken shortly after apprehension in all cases, and the concentrations were in the higher range among those from our population of recreational users. The subjects also presented with severe symptoms and several were unconscious when found. Somnolence was also one of the most common neurological effects reported by Hermanns-Clausen et al. (39) in a series of hospitalized intoxications. Subjects with only JWH-018 present had concentrations between 0.4 and 13 ng/mL serum, which is in the same range as our subjects (1.3 and 11 ng/g whole blood). These concentrations, an hour or more after smoking, seem high compared with those obtained as peak within minutes of controlled smoking as reported by Kacinko et al. (33) (5 ng/mL for JWH-018 in whole blood 19 min after smoking). Therefore, high doses may explain the severe symptoms in our subjects. Compared with cannabis sativa, the dosing of synthetic cannabinoids may be difficult as the application of the active substances on dried plant material may very well not be homogenous within or between batches of products. Besides the high-affinity and high-efficacy CB1R agonist properties, this may also contribute to the risk of adverse effects. Overdosing might even, under some circumstances, result in death as exemplified by the fatal intoxication described. In this case, the very potent CB1R agonist, JWH-210, was found in a high concentration in femoral blood. No other drugs or alcohol were found in the toxicological analyses. We believe that the acute effects of the synthetic cannabinoids played a significant role in the demise of this young man. 
Conclusions
In general, the median concentrations of the synthetic cannabinoids were ,0.5 ng/g blood and require very sensitive methods in routine work. Tandem mass spectrometry is a requirement and the diversity of analytes makes it difficult to use only one extraction and detection method to cover the whole range of cannabinoids in a quantitative method. For the toxicology laboratory, target methods quickly become less useful when the drug panorama changes. For the future, a more general untargeted method might be a better approach to counter the continuous change in substances. We are now investigating the use of LC-QTOF for the untargeted screening of synthetic cannabinoids in blood and urine. The toxicity of the synthetic cannabinoids seems to be worse than that of natural cannabis probably owing to the higher potency and perhaps also to the presence of several different cannabinoids in the smoked incense and the difficulties of proper dosing. The acute toxic effects may, under certain circumstances, contribute to death.
